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1. Introduction {#efs25012-sec-0002}
===============

1.1. Background and Terms of Reference as provided by the requestor {#efs25012-sec-0003}
-------------------------------------------------------------------

### 1.1.1. Background {#efs25012-sec-0004}

The use of flavourings is regulated under Regulation (EC) No 1334/2008[1](#efs25012-note-1005){ref-type="fn"} of the European Parliament and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and approval are required for flavouring substances.

The Union list of flavourings and source materials was established by Commission Implementing Regulation (EC) No 872/2012[2](#efs25012-note-1006){ref-type="fn"}.

The substance benzophenone, \[FL no. 07.032\] (CAS No. 119‐61‐9) is currently included in this Union List. It is a substance which is not currently under evaluation. This substance is also known as diphenyl ketone. This substance was included in the Union list on the basis of the EFSA evaluation in FGE 69 of 2008. FGE 69 includes this substance. Benzophenone was evaluated by JECFA as a flavouring substance, with JECFA no. 831. The studies evaluated by IARC were not considered in the EFSA opinion on FGE 69. There may be also additional studies on the safety of this substance.

The substance ethyl acrylate, \[FL no. 09.037\], (CAS No. 140‐88‐5) was included in the Union list on the basis of the EFSA evaluation in FGE 71 of 2010. FGE.71 includes this substance. Ethyl acrylate was evaluated by JECFA as a flavouring substance, with JECFA no. 1351. The studies evaluated by IARC were not considered in the EFSA opinion of FGE.71. There may be also additional studies on the safety of this substance.

### 1.1.2. Terms of Reference {#efs25012-sec-0005}

In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002[3](#efs25012-note-1007){ref-type="fn"}, the European Commission requests the European Food Safety Authority (EFSA) to carry out a review of existing published literature on the safety of the flavouring substances benzophenone, \[FL. No 07.032\], (CAS No. 119‐61‐9) and ethyl acrylate, \[FL 09.037\], (CAS No. 140‐88‐5), and advise on their safety when used as flavouring substances.

1.2. Interpretation of the Terms of Reference {#efs25012-sec-0006}
---------------------------------------------

Since benzophenone \[FL‐ no: 07.032\] and ethyl acrylate \[FL‐no: 09.037\] are not structurally related and were evaluated in different FGEs (FGE.69 and FGE.71), they will be evaluated in separate opinions. The present document will address the question of the Commission on ethyl acrylate. Meanwhile, EFSA has also received information on use levels which will be taken into consideration. Considering the Term of Reference, the Panel will not address in this assessment, the exposure that may result from the use as food contact material.

In respect to the approach to be followed for the assessment of ethyl acrylate used as a flavouring substance, the Panel was of the view that previous assessments should be used as starting points for this scientific opinion. The previous assessment will be updated with new information that is connected to the concerns identified in the background (Section [1.1](#efs25012-sec-0003){ref-type="sec"}).

In the background (Section [1.1](#efs25012-sec-0003){ref-type="sec"}), it is mentioned that the studies evaluated by IARC in the report from 1999 on carcinogenicity of ethyl acrylate were not considered in the EFSA evaluation from 2010, and that there may be additional studies on the safety of ethyl acrylate when used as a flavouring substance. Thus, the present evaluation is mainly focusing on the genotoxicity and carcinogenicity of ethyl acrylate, in addition to considering any new data on toxicity, which may have an impact on the safety assessment of ethyl acrylate as flavouring. Moreover, previous assessments of ethyl acrylate by JECFA ([2006](#efs25012-bib-0022){ref-type="ref"}) and EFSA (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}) are briefly presented.

According to the request from the Commission (Section [1.1](#efs25012-sec-0003){ref-type="sec"}), the present evaluation will be based on available data on ethyl acrylate. Acrylic acid is a metabolite of ethyl acrylate and in that sense also the safety of acrylic acid is included in this evaluation. However, the safety of exposure directly to acrylic acid will not be evaluated in the present opinion, which according to the terms of reference will address the use of ethyl acrylate as a flavouring substance.

2. Data and methodologies {#efs25012-sec-0007}
=========================

The search for literature was done by EFSA on ethyl acrylate \[FL‐no: 09.037\] to review existing literature on the safety of this substance and to advise on its safety when used as flavouring substance. A literature search was carried out through Web of Science database until August 2017, using keywords "ethyl acrylate" or "140‐88‐5" and "genotox\*", "canc\*", "carc\*", "tumor\*", "toxicokin\*", "metabol\*", "absorb\*", "distrib\*", "excret\*", and "reproduct\*" while searching in "all databases". Additional searches were carried out through Scopus database, using the keyword combination of "ethyl acrylate" and "tox", and the database of Decernis, using the keyword "140‐88‐5".

3. Procedure of the safety assessment {#efs25012-sec-0008}
=====================================

3.1. Assessment {#efs25012-sec-0009}
---------------

The Panel considered studies already evaluated (JECFA, [2006](#efs25012-bib-0022){ref-type="ref"}; EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}) and additional studies from literature search. Except for genotoxicity, no new relevant studies were identified for short‐term toxicity, chronic toxicity and carcinogenicity.

3.2. Technical data {#efs25012-sec-0010}
-------------------

Information on the identity of the substance and specifications are based on data already described in FGE.71 (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}) and are presented in Table [1](#efs25012-tbl-0001){ref-type="table"}.

###### 

Summary of specifications for the substance ethyl acrylate (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"})

+----------------+------------------+--------------------------------------+-----------------------+-------------------------------------+----------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+
| FL‐no JECFA‐no | EU Register name | Structural formula                   | FEMA no CoE no CAS no | Phys. Form Mol. Formula Mol. weight | Solubility[a](#efs25012-note-0006){ref-type="fn"} Solubility in ethanol[b](#efs25012-note-0007){ref-type="fn"} | Boiling point, °C[c](#efs25012-note-0008){ref-type="fn"} Melting point, °C ID test Assay minimum | Refrac. Index[d](#efs25012-note-0009){ref-type="fn"} Spec. gravity[e](#efs25012-note-0010){ref-type="fn"} |
+================+==================+======================================+=======================+=====================================+================================================================================================================+==================================================================================================+===========================================================================================================+
| 09.037         | Ethyl acrylate   | ![](EFS2-15-e05012-g001.jpg "image") | 2418                  | Liquid                              | Slightly Soluble                                                                                               | 99--101                                                                                          | 1.403--1.409                                                                                              |
|                |                  |                                      |                       |                                     |                                                                                                                |                                                                                                  |                                                                                                           |
| 1351           |                  |                                      | 245                   | C5H8O2                              | Soluble                                                                                                        | IR                                                                                               | 0.916--0.919                                                                                              |
|                |                  |                                      |                       |                                     |                                                                                                                |                                                                                                  |                                                                                                           |
|                |                  |                                      | 140‐88‐5              | 100.12                              |                                                                                                                | 97%                                                                                              |                                                                                                           |
+----------------+------------------+--------------------------------------+-----------------------+-------------------------------------+----------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+

FL‐no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract Service; ID: Identity; IR: infrared spectroscopy.

Solubility in water, if not otherwise stated.

Solubility in 95% ethanol, if not otherwise stated.

At 1013.25 hPa, if not otherwise stated.

At 20°C, if not otherwise stated.

At 25°C, if not otherwise stated.

John Wiley & Sons, Ltd

3.3. Information on existing evaluations from EFSA {#efs25012-sec-0011}
--------------------------------------------------

Ethyl acrylate \[FL‐no: 09.037\] has been evaluated by JECFA ([2006](#efs25012-bib-0022){ref-type="ref"}), EFSA considered this evaluation and concluded, in FGE.71, that ethyl acrylate is of no safety concern at estimated level of intake as flavouring substance based on the Maximised Survey‐Derived Daily Intake (MSDI) approach (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}).

Ethyl acrylate was evaluated as a substance in food contact materials (FCM) by the Scientific Committee for food (SCF, [1999](#efs25012-bib-0043){ref-type="ref"}). They established a group temporary tolerable daily intake (TDI) of 0.1 mg/kg body weight (bw) for several acrylates, expressed as acrylic acid. The temporary TDI was based on data from experimental animals exposed to acrylic acid. Based on this TDI, a specific migration limit (SML) of 6 mg/kg of food was calculated for the group of substances that share acrylic acid as a common metabolite/degradation product.

In Regulation (EU) No 10/2011[4](#efs25012-note-1008){ref-type="fn"}, ethyl acrylate is an approved monomer for use in FCM with a group SML for the sum of substances that have acrylic acid as a common metabolite/degradation product of 6 mg/kg of food.

3.4. Exposure {#efs25012-sec-0012}
-------------

### 3.4.1. Concentration in processed and non‐processed foods from natural sources {#efs25012-sec-0013}

Ethyl acrylate \[FL‐no: 09.037\] has been reported to occur in passion fruit, pineapple, Beaufort cheese and durian (IARC, [1999a](#efs25012-bib-0019){ref-type="ref"}, Triskelion, [2017](#efs25012-bib-0045){ref-type="ref"}). Quantitative data are reported for ethyl acrylate in pineapple (0.01 mg/kg) (Triskelion, [2017](#efs25012-bib-0045){ref-type="ref"}).

### 3.4.2. Chronic dietary exposure {#efs25012-sec-0014}

The exposure assessment to be used in the Procedure for the safety evaluation of the candidate substance is the chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, [2010b](#efs25012-bib-0005){ref-type="ref"}). The chronic APET for ethyl acrylate has been calculated for adults and children (see Table [2](#efs25012-tbl-0002){ref-type="table"} and Appendix [C](#efs25012-sec-1003){ref-type="sec"}). The chronic APET calculation is based on the combined normal occurrence level.

The Panel noted that the contribution from natural occurrence of ethyl acrylate to the APET is negligible compared to the added flavouring substance.

###### 

APET -- Chronic dietary exposure

  Chronic APET                                      Added[a](#efs25012-note-0012){ref-type="fn"}   Other dietary sources[b](#efs25012-note-0013){ref-type="fn"}   Combined[c](#efs25012-note-0014){ref-type="fn"}                 
  ------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------- ------------------------------------------------- ------ ------ -------
  Adults[d](#efs25012-note-0015){ref-type="fn"}     59.1                                           3,545                                                          0.23                                              14.0   59.1   3,545
  Children[e](#efs25012-note-0016){ref-type="fn"}   149                                            2,233                                                          0.59                                              8.85   149    2,233

APET: added portions exposure technique; bw: body weight.

APET Added is calculated on the basis of the normal amount of flavour added to a specific food category.

APET Other Dietary Sources is calculated based on the natural occurrence of the flavouring in a specified food category.

APET Combined is calculated based on the combined amount of added flavouring and naturally occurring flavouring in a specified food category.

For the adult APET calculation, a 60‐kg person is considered representative.

For the child APET calculation, a 3‐year old child with a 15 kg bw is considered representative.

John Wiley & Sons, Ltd

The Panel noted that exposure to ethyl acrylate may also occur from FCM (SML 6 mg/kg food, as acrylic acid, corresponding to a maximum exposure of 6 mg/person per day; see Section [3.3](#efs25012-sec-0011){ref-type="sec"}).

### 3.4.3. Acute dietary exposure {#efs25012-sec-0015}

Acute exposure is not evaluated, because this opinion addresses only chronic exposure.

3.5. Biological and toxicological data {#efs25012-sec-0016}
--------------------------------------

The toxicity of ethyl acrylate has been evaluated by JECFA in 2006 and concerning genotoxicity by EFSA (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}). The carcinogenicity was evaluated by IARC in 1999a. Brief summaries of the previous evaluations will follow below and data not previously considered will be presented.

3.6. Absorption, distribution, metabolism and excretion {#efs25012-sec-0017}
-------------------------------------------------------

Ethyl acrylate is the ethyl ester of acrylic acid. Aliphatic esters formed from 2‐alkenoic acids are generally rapidly hydrolysed to respective alcohols and carboxylic acids by carboxylesterases. Thus, ethyl acrylate is hydrolysed to acrylic acid and ethanol, which will participate in biochemical pathways, including the fatty acid pathway and tricarboxylic acid cycle (see review by JECFA, [2006](#efs25012-bib-0022){ref-type="ref"}).

[*In vitro* studies]{.ul}

Miller et al. ([1981](#efs25012-bib-0028){ref-type="ref"}) compared the rate of hydrolysis of ethyl acrylate in homogenates of different tissues and found the highest rate in liver, followed by whole blood, lung and kidney. In the liver homogenate, the hydrolysis rate of ethyl acrylate was 26.8 nmol/min. Potter and Tran ([1992](#efs25012-bib-0040){ref-type="ref"}) demonstrated that ethyl acrylate reacts with both glutathione (GSH) and protein *in vitro*.

[*In vivo* studies]{.ul}

^14^C‐Ethyl acrylate has been used for metabolic studies (DeBethizy et al., [1987](#efs25012-bib-0003){ref-type="ref"}). Rats were administered single oral doses of 2, 20 and 200 mg/kg bw and radioactivity was followed during 72 h. A rapid and high absorption was demonstrated and most of the radioactivity was exhaled as CO~2~ (52--62% of dosed radioactivity) and almost all during the first 10 h after administration. The detection of 3‐hydroxypropionic acid as a urinary metabolite led to the suggestion by the authors, that acrylic acid was incorporated into propionic acid metabolism, explaining the rapid formation of carbon dioxide. In urine two metabolites derived from GSH conjugation were also detected. At the two lower doses of ethyl acrylate, non‐protein sulfhydryl (NPSH) content decreased significantly at the dosing site, forestomach and glandular stomach, but not in the liver. NPSH, mainly GSH, cysteine, coenzyme A and other thiols in the gastric mucosa, are suggested to play an important role in the protection of gastric mucosa against chemically‐induced lesions (Nagy et al., [2007](#efs25012-bib-0032){ref-type="ref"}).

Oral dosing of rats with ethyl acrylate was performed in a study by Frederick et al. ([1992](#efs25012-bib-0010){ref-type="ref"}) to validate a physiologically based pharmacokinetic and pharmacodynamics model for ethyl acrylate. The predicted very rapid metabolism was verified and consistent with the finding that no ethyl acrylate could be detected in tissues. The model also predicted glutathione depletion in forestomach.

Overall, ethyl acrylate is rapidly absorbed, metabolised, incorporated into endogenous biochemical pathways and excreted.

### 3.6.1. Short‐term and subchronic toxicity {#efs25012-sec-0018}

A single dose of 100, 200 or 400 mg/kg bw ethyl acrylate administered by gavage to F344 rats caused mucosal and submucosal oedema and vacuolisation of the tunica muscularis in the forestomach and mild submucosal oedema in the glandular stomach (Ghanayem et al., [1985](#efs25012-bib-0011){ref-type="ref"}). No gastric effects were observed after equivalent subcutaneous or intraperitoneal (i.p.) doses. After 2 or 4 consecutive daily doses of 200 mg/kg bw similar effects were observed, and in addition submucosal inflammation, mucosal erosions or ulcers in both portions of the stomach. There was no systemic toxicity. The same authors (Ghanayem et al., [1986](#efs25012-bib-0012){ref-type="ref"}) also studied the recovery of the lesions in rats after 14 daily gavage doses of 100 or 200 mg/kg bw ethyl acrylate. After 14 days of exposure, the glandular stomach was normal in all animals and appeared to have adapted to resist the toxicity of ethyl acrylate. The forestomach exhibited dose‐dependent lesions, which were recovered in the low dose group at 14 days following the last dose, while in the high dose group mucosal hyperplasia was still present in the forestomach at 4 weeks after last exposure.

Male F344/N rats were dosed with ethyl acrylate either by gavage at doses from 2 to 200 mg/kg bw daily for 2 weeks or via drinking water at concentrations from 200 to 4,000 mg/L (corresponding to 23--369 mg/kg bw/day, according to the authors) (Frederick et al., [1990](#efs25012-bib-0009){ref-type="ref"}). A dose‐dependent increase in irritation of the forestomach was observed in the animals dosed by gavage, while the animals dosed via drinking water had a much lower incidence and less severe lesions at the corresponding dose levels. There were no lesions in the glandular stomach. Severe depletion of NPSH was observed in the forestomach at gavage doses ≥ 100 mg/kg bw, while no significant depletion was seen after administration via drinking water. The NPSH depletion in glandular stomach and liver were lower, and not at levels generally associated with toxicity. The authors suggested that the depletion of NPSH in the rat forestomach was causally related to the histopathology observed at relatively high doses. Thus, at doses of 100 mg/kg bw per day or greater by gavage, the NPSH content was severely depleted (below 25% of the initial concentration) and moderate to marked hyperplasia was observed together with ulceration and erosion of the forestomach epithelium. Minimal depletion of NPSH, producing minimal to mild hyperplasia, was reported at 20--50 mg/kg bw. At 10 mg/kg bw and less, no significant NPSH depletion and no histopathological findings were reported.

To design the 2‐year carcinogenesis study on ethyl acrylate, the NTP performed several 14‐day and 13‐week gavage studies in B6C3F~1~ mice and F344/N rats (NTP, [1986](#efs25012-bib-0033){ref-type="ref"}). The principal toxic effect in the 14‐day studies was in the forestomach of both sexes in mice and rats. There was no evidence of systemic toxicity. The lowest dose where histological lesions in the forestomach were detected was 400 mg/kg bw in rats and 200 mg/kg bw in mice.

Sustainability of forestomach hyperplasia was studied in rats treated with ethyl acrylate for 13 weeks with gavage doses of 100 or 200 mg/kg bw per day (Ghanayem et al., [1991](#efs25012-bib-0013){ref-type="ref"}). Severe hyperplasia of the forestomach was observed after 13 weeks. No effects were detected in the glandular stomach or liver. A significant decline in incidence and severity of the hyperplasia was reported in rats after a recovery period of 8 weeks without treatment and a further decline in effects were seen after 13 weeks.

Overall, severe irritation of the forestomach and mild oedema of the glandular stomach resulted from a single dose of ethyl acrylate, administered by gavage. In short‐term and subchronic gavage studies, histological lesions were observed in the forestomach but not in the glandular stomach. The histopathological lesions in the forestomach were associated to NPSH depletion. After cessation of exposure, there was a dose‐dependent recovery of the forestomach lesions. Exposure of ethyl acrylate via drinking water caused lower incidence and less severe forestomach lesions. No gastric effects were observed after parenteral administrations. There was no evidence of systemic toxicity.

### 3.6.2. Genotoxicity {#efs25012-sec-0019}

#### Summary of *in vitro* data assessed in FGE.71 {#efs25012-sec-0020}

*In vitro* genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}), based on JECFA evaluation (2006) and are summarised in Appendix [A](#efs25012-sec-1001){ref-type="sec"}, Table [A.1](#efs25012-tbl-0003){ref-type="table"}.

Negative results were reported in Ames assays when *Salmonella* Typhimurium strains (TA97, TA98, TA100, TA1535, TA1537 and TA1538) were incubated with ethyl acrylate \[FL‐no: 09.037\] at concentrations up to 10,000 μg/plate (Ishidate et al., [1981](#efs25012-bib-0021){ref-type="ref"}; Waegemaekers and Bensink, [1984](#efs25012-bib-0047){ref-type="ref"}; Tennant et al., [1987](#efs25012-bib-0044){ref-type="ref"}; Zeiger et al., [1992](#efs25012-bib-0051){ref-type="ref"}).

No evidence of mitotic chromosomal loss was obtained when ethyl acrylate at concentrations up to 1,095 μg/mL was incubated with *Saccharomyces cerevisiae* strain D61.M. Under a cold shock regimen, evidence of mitotic recombination was reported (Zimmermann and Mohr, [1992](#efs25012-bib-0052){ref-type="ref"}).

In the standard assay for forward mutation in mouse lymphoma cells, ethyl acrylate gave uniformly positive results in the absence of metabolic activation when tested with mouse lymphoma L5178Y Tk+ cells at cytotoxic concentrations (37.5--50 μg/mL) associated with a reduction of the relative total growth by 50--60% (Tennant et al., [1987](#efs25012-bib-0044){ref-type="ref"}; McGregor et al., [1988](#efs25012-bib-0027){ref-type="ref"}; Moore et al., [1988](#efs25012-bib-0029){ref-type="ref"}; Ciaccio et al., [1998](#efs25012-bib-0002){ref-type="ref"}). In assays for clastogenicity, ethyl acrylate elicited increases in sister chromatid exchanges (SCE) and chromosomal aberrations (CA) in Chinese hamster ovary (CHO) cells with metabolic activation, but showed no evidence of clastogenicity in the absence of metabolic activation (Loveday et al., [1990](#efs25012-bib-0026){ref-type="ref"}). The clastogenic potential was unaffected by changes in harvest time (Loveday et al., [1990](#efs25012-bib-0026){ref-type="ref"}). Ethyl acrylate induced an increase in SCE and CA in mouse lymphoma cells in a dose‐dependent manner, beginning at 20 μg/mL, in the absence of metabolic activation (Moore et al., [1988](#efs25012-bib-0029){ref-type="ref"}). An increase in SCE and CA in CHO cells was also reported in another study with ethyl acrylate at concentrations of 150 and 299 μg/mL, respectively, with metabolic activation (Tennant et al., [1987](#efs25012-bib-0044){ref-type="ref"}). There was no evidence of clastogenicity in the absence of metabolic activation (Tennant et al., [1987](#efs25012-bib-0044){ref-type="ref"}). Increases in CA were reported at 9.8 μg/mL in Chinese hamster cells with or without metabolic activation (Ishidate et al., [1981](#efs25012-bib-0021){ref-type="ref"}).

#### *In vitro* data not previously considered {#efs25012-sec-0021}

*In vitro* genotoxicity studies, previously not considered in the EFSA evaluation are summarised in Appendix [B](#efs25012-sec-1002){ref-type="sec"}, Table [B.1](#efs25012-tbl-0004){ref-type="table"}.

Ethyl acrylate tested up to 5,000 μg/plate was negative in *S. *Typhimurium strain TA102 (Kirkland et al., [2016](#efs25012-bib-0024){ref-type="ref"}).

Ethyl acrylate tested up to 2,000 μg/plate in the *S*. Typhimurium strain YG7108 (*ogt*−, *ada*−) (mutant of TA1535 strain deficient in methyl transferase), transformed with the plasmid pin3ERb5, encoding for a complete electron transport chain, comprising P450 reductase, cytochrome b5 and cytochrome P450 2E1, did not induce any significant increase of the revertants (Emmert et al., [2006](#efs25012-bib-0006){ref-type="ref"}).

A number of studies are available on *in vitro* micronucleus (MN) assay in different rodent (V79, CHL, CHO and L5178Y) and human cell lines, p53 competent and p53 mutated, in the presence and absence of cytochalasin B (Fowler et al., [2012a](#efs25012-bib-0007){ref-type="ref"},[b](#efs25012-bib-0008){ref-type="ref"}; Whitwell et al., [2015](#efs25012-bib-0049){ref-type="ref"}). Ethyl acrylate was tested at different concentrations up to 55% of cytotoxicity for 3 h followed by recovery and for 24 h without recovery. The results showed increases of frequencies of micronucleated cells in rodent p53‐deficient cell lines. Following treatment of human cell lines WIL2‐NS (with mutated p53) and TK6 (with wild‐type p53) using the cytochalasin‐blocked cytokinesis assay, the majority of concentrations tested resulted in micronucleated cell frequencies similar to the control values, with single exceptions, characterised by a marginal increase at intermediate concentrations.

Using an alternative protocol in the absence of cytochalasin B following treatment of WIL2‐NS and TK6 cells with ethyl acrylate, normal frequencies of mononucleated cells with MN were observed for all concentrations including those inducing 53% and 66% cytotoxicity, respectively, fulfilling the criteria for clear negative responses. In contrast, small but statistically significant increases in MN frequency were observed at the highest two concentrations analysed following treatment of L5178Y cells. Significant increases in caspase activity (greater than threefold over the vehicle control) associated with high level of toxicity were observed in TK6 cells after treatment with ethyl acrylate, suggesting apoptosis as a mechanism of induction of micronuclei frequencies (Fowler et al., [2012a](#efs25012-bib-0007){ref-type="ref"},[b](#efs25012-bib-0008){ref-type="ref"}; Whitwell et al., [2015](#efs25012-bib-0049){ref-type="ref"}).

#### Summary of *in vivo* data assessed in FGE.71 {#efs25012-sec-0022}

*In vivo* genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, [2010a](#efs25012-bib-0004){ref-type="ref"}), based on JECFA evaluation (2006) and are summarised in Appendix [A](#efs25012-sec-1001){ref-type="sec"}, Table [A.1](#efs25012-tbl-0003){ref-type="table"}.

Single oral doses of ethyl acrylate at concentrations up to 4% were administered to male F344 rats (Morimoto et al., [1990](#efs25012-bib-0030){ref-type="ref"}). The forestomach exhibited oedema and inflammation, but no DNA damage was detected by alkaline elution.

In an *in vivo‐in vitro* assay for clastogenicity, C57BL/6 male mice were given ethyl acrylate at doses of 0, 125, 250, 500 or 1,000 mg/kg bw by i.p. injection (Kligerman et al., [1991](#efs25012-bib-0025){ref-type="ref"}). Twenty‐four hours later, animals were sacrificed, splenocytes were isolated and concanavalin A was added to stimulate cell division. In half cultures, bromodeoxyuridine was added for the analysis of CA in the first division cells, and SCE in the second division cells. In the remaining cultures, cytochalasin B was added for the scoring of MN in binucleated cells. No significant increase of CA and SCE was reported, while ethyl acrylate did induce a statistically significant increase of binucleated cells with MN (less than twofolds with respect to the control value) only at the highest dose (1,000 mg/kg bw); according to the study authors, this increase was apparently due to a relatively high response in one of five animals. The highest dose tested in this study is fivefold higher than the highest dose (200 mg/kg bw) used in the carcinogenicity study by the National Toxicology Program (1986) (Kligerman et al., [1991](#efs25012-bib-0025){ref-type="ref"}).

Although an early report (Przybojewska et al., [1984](#efs25012-bib-0042){ref-type="ref"}) indicated that ethyl acrylate was genotoxic in a standard MN test in mice, subsequent studies (Ashby et al., [1989](#efs25012-bib-0001){ref-type="ref"}; Kligerman et al., [1991](#efs25012-bib-0025){ref-type="ref"}; Hara et al., [1994](#efs25012-bib-0017){ref-type="ref"}; Morita et al., [1997](#efs25012-bib-0031){ref-type="ref"}) confirmed that ethyl acrylate exhibits no genotoxic potential in this assay. An increase in the incidence of polychromatic erythrocytes (PCE) with MN was reported in bone marrow of BALB/C male mice treated with ethyl acrylate at doses of 225--1,800 mg/kg bw by i.p. injection in two doses separated by 24 h. A statistically significant decrease of the ratio between PCEs and normochromatic erythrocytes (NCEs) was observed in the same range of doses, indicating bone marrow toxicity (Przybojewska et al., [1984](#efs25012-bib-0042){ref-type="ref"}). There was no evidence of increase in MN cells collected 24 h after groups of six BDF1 male mice were given ethyl acrylate as a single or two doses at 0, 188, 375 or 750 mg/kg bw by oral gavage or when ethyl acrylate was administered as a single dose at 0, 375, 500 or 750 mg/kg bw by i.p. injection. A statistically significant reduction of reticulocyte percent after double oral gavage and i.p. administration at 750 mg/kg was reported (Hara et al., [1994](#efs25012-bib-0017){ref-type="ref"}). In another MN test, groups of five male and five female C57BL/6 mice were given ethyl acrylate as a single i.p. dose at 461 or 738 mg/kg bw and samples were collected at 24, 48 (738 mg/kg bw dose only) and 72 h (738 mg/kg bw dose only) (Ashby et al., [1989](#efs25012-bib-0001){ref-type="ref"}). In subsequent experiments, groups of 5--10 male C57BL/6 and BALB/c mice were given ethyl acrylate at a dose of 738 or 812 mg/kg bw in two doses administered by i.p. injection within 24 h, and erythrocytes were sampled at 30 h. In none of these experiments, there was any evidence of increase in MN PCE in bone marrow of mice (Ashby et al., [1989](#efs25012-bib-0001){ref-type="ref"}). Negative results were obtained for MN induction when groups of six male BDF1 mice were given ethyl acrylate either as a single oral dose (188, 375 or 750 mg/kg bw) or a single intraperitoneal dose (188 or 375 mg/kg bw) and samples of bone marrow were collected after 24 h (Morita et al., [1997](#efs25012-bib-0031){ref-type="ref"}).

In an assay for mutagenicity *in vivo* in *Drosophila melanogaster*, there was no evidence of increase in sex‐linked recessive lethals in three successive broods obtained from Basc virgin females mated with Canton‐S wild‐type males either injected with ethyl acrylate at a concentration of 20,000 mg/kg or fed a solution containing ethyl acrylate at a concentration of 40,000 mg/kg for 3 days. In a second experiment, there was no evidence of mutagenicity when *D. melanogaster* were fed a solution containing ethyl acrylate at a concentration of 18,000 or 20,000 mg/kg (Valencia et al., [1985](#efs25012-bib-0046){ref-type="ref"}).

#### *In vivo* data not previously considered {#efs25012-sec-0023}

No new data are available.

#### Conclusions on genotoxicity {#efs25012-sec-0024}

Overall, the Panel considered that based on the available data, which covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations), there is no concern with respect to genotoxicity of ethyl acrylate.

### 3.6.3. Chronic toxicity and carcinogenicity {#efs25012-sec-0025}

Carcinogenesis studies of ethyl acrylate was performed by NTP in B6C3F~1~ mice and F344/N rats given the test compound in corn oil by gavage at doses of 100 and 200 mg/kg bw per day, 5 days per week, for 103 weeks (NTP, [1986](#efs25012-bib-0033){ref-type="ref"}). There was no evidence of toxicity at any other sites than the forestomach. A dose‐related increase in the incidences of hyperkeratosis, hyperplasia and inflammation of the forestomach were reported in both sexes and both species, in addition to a statistically significant positive trend in the incidence of squamous cell carcinoma and papilloma in the forestomach. The incidence of tumours in the forestomach was higher in rats than in mice, which was explained by a twofold higher concentration of ethyl acrylate in the gavage solution for rats than for mice, in the 2‐year study. Statistically significant negative trends were reported for several tumours, such as hepatocellular carcinoma, follicular cell tumour of the thyroid and lymphocytic lymphoma in male mice. The conclusions from NTP ([1986](#efs25012-bib-0033){ref-type="ref"}) were 'Under the conditions of these studies, ethyl acrylate was carcinogenic for the forestomach of F344/N rats and B6C3F~1~ mice, causing squamous cell carcinomas in male rats and male mice, and squamous cell papillomas or carcinomas (combined) in male and female rats and mice. Evidence for carcinogenicity was greater in males than in females. Ethyl acrylate also caused irritation of the forestomach mucosa in male and female rats and mice'.

This conclusion was later modified (NTP, [1998](#efs25012-bib-0034){ref-type="ref"}), with the following recommendation 'It is recommended that ethyl acrylate be delisted from the Report on Carcinogens because the forestomach tumors, induced in animal studies, were seen only when the chemical was administered by gavage at high concentrations of ethyl acrylate, that induced marked local irritation and cellular proliferation and because significant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely'.

Ghanayem et al. ([1993](#efs25012-bib-0014){ref-type="ref"}, [1994](#efs25012-bib-0015){ref-type="ref"}) studied the time required for sustained forestomach hyperplasia to produce neoplastic lesions in F344 rats administered ethyl acrylate at 200 mg/kg bw per day, 5 days per week, by gavage for 6 or 12 months. The increase in epithelial hyperplasia of the forestomach sustained as long as the exposure continued. However, the hyperplasia regressed and no neoplasms developed, when exposure was stopped after 6 months and the animals were allowed to recover until they were sacrificed at 24 months of age. In contrast, forestomach squamous cell carcinoma developed in rats treated for 12 months and allowed to recover for 9 months.

Acrylic acid, a metabolite of ethyl acrylate, was given to Wistar rats during 12 months in drinking water, containing 120, 800, 2,000 or 5,000 mg/L, providing doses of about 9, 61, 140 and 331 mg/kg bw per day, according to the authors (Hellwig et al., [1993](#efs25012-bib-0018){ref-type="ref"}). The two highest doses led to reduced consumption of drinking water, indicating palatability problems. There were no indications of systemic toxicity or carcinogenicity. Another study was performed in rats for 26 (males) and 29 (females) months with drinking water concentrations of 120, 400 or 1,200 mg/L, providing doses of 8, 27 or 78 mg/kg bw per day. There were no indications of toxic changes or carcinogenic potential.

Overall, increases in forestomach squamous cell papilloma and carcinoma were reported in rats and mice, when ethyl acrylate was administered via gavage. The neoplasms were preceded by extreme sustained irritation of the epithelium, which was reversible when exposure was stopped after 6 months but not after 12 months. There was no evidence of systemic toxicity.

### 3.6.4. Discussion {#efs25012-sec-0026}

The NTP carcinogenicity studies from 1986 concluded that ethyl acrylate administered by gavage was carcinogenic for the forestomach of mice and rats due to increases in forestomach squamous cell papilloma and carcinoma. The lesions were related to the concentration of ethyl acrylate in dosing solutions. Severe irritation of the forestomach was seen after single oral administration of ethyl acrylate. Hyperkeratosis, inflammation and hyperplasia of the forestomach were observed in subchronic and 2‐year gavage studies. There were no gastric lesions after parenteral administration and no evidence of systemic toxicity in any of the studies. The Panel considered the observed local forestomach lesions to be a consequence of the known irritating properties of ethyl acrylate.

The conclusion on carcinogenicity of ethyl acrylate from the NTP studies was revised in 1998, when NTP recommended ethyl acrylate to be 'delisted from the Report on Carcinogens because the forestomach tumors, induced in animal studies, were seen only when the chemical was administered by gavage at high concentrations of ethyl acrylate, that induced marked local irritation and cellular proliferation and because significant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely'. This conclusion was supported by Williams and Iatropoulos ([2009](#efs25012-bib-0050){ref-type="ref"}), who further emphasised that the route and rate of ethyl acrylate exposure in rodents for forestomach neoplasia are not relevant to humans, since humans do not have forestomach and are not exposed to ethyl acrylate by oral bolus.

Based on experimental data (publications up to 1993) in rodents showing lesions and carcinoma of forestomach, IARC ([1999a](#efs25012-bib-0019){ref-type="ref"}) classified ethyl acrylate as possibly carcinogenic to humans (Group 2B). It should be noted, that IARC monographs are intended to be hazard evaluations, that is to identify whether a substance can be associated with the development of cancer, regardless of the dose or exposure conditions at which an increased risk occur (Goodman and Lynch, [2017](#efs25012-bib-0016){ref-type="ref"}). In the mechanistic considerations, IARC ([1999a](#efs25012-bib-0019){ref-type="ref"}) noted that ethyl acrylate was clastogenic *in vitro*, but not *in vivo*.

The predictive value of rodent forestomach tumours in evaluating carcinogenic risks to humans was discussed by IARC ([1999b](#efs25012-bib-0020){ref-type="ref"}), which considered in particular exposure conditions and tissue specificity. Exposure conditions should be considered, especially if oral gavage is used, because it can result in high local concentration of the test substance in the forestomach and prolonged exposure of the epithelial tissue. 'Agents that produce tumors in rodent forestomach only after prolonged exposure through non‐DNA reactive mechanisms, may be less relevant to humans because human exposure would have to overcome time‐integrated dose thresholds to result in a carcinogenic response' (IARC, [1999b](#efs25012-bib-0020){ref-type="ref"}).

In the present safety evaluation, genotoxicity of ethyl acrylate was assessed from all available data, both previously assessed and previously not considered. Ethyl acrylate was negative in bacterial reverse mutation assays. Ethyl acrylate resulted positive when tested in some *in vitro* assays for gene mutation and CA in mammalian cells, however, in *in vivo* studies no genotoxicity effects were observed as also reported for other acrylates (Johannsen et al., [2008](#efs25012-bib-0023){ref-type="ref"}). Therefore, based on the available data, which covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations), the Panel considers that there is no concern with respect to genotoxicity of ethyl acrylate.

The Panel agrees with the NTP re‐evaluation (1998) and considers that the forestomach squamous cell papilloma and carcinoma are preceded by extreme sustained irritation of the epithelium, which is reversible when exposure is stopped after 6 months but not after 12 months. No lesions are observed in the glandular stomach. Moreover, in short‐term, subchronic and chronic toxicity studies, there was no evidence of systemic toxicity.

The initiating events for the effects in the forestomach involve depletion of NPSH, which was observed in the forestomach at gavage doses \>100 mg/kg bw per day, while no significant depletion was seen after administration via drinking water at 200--4,000 mg/L (Frederick et al., [1990](#efs25012-bib-0009){ref-type="ref"}). The depletion of NPSH in the rat forestomach was related to the histopathology observed at relatively high doses. At 10 mg/kg bw and less, no significant NPSH depletion and no histopathological findings were reported.

The estimated chronic dietary exposure of ethyl acrylate in adults and children were 60 and 150 μg/kg bw per day, respectively, calculated by the APET approach, with minimal contribution from natural occurring flavour in food. Maximum exposure from FCM may be up to 100 μg/kg bw per day.

The Panel considers that the forestomach tumours, observed in rodents, are not a relevant toxicological endpoint to humans since they are not exposed to ethyl acrylate by oral bolus. Furthermore, there is an absence of correlation between forestomach in rats and oesophageal lesions in humans, as reported in the reviews by Wester and Kroes ([1988](#efs25012-bib-0048){ref-type="ref"}) and Proctor et al. ([2007](#efs25012-bib-0041){ref-type="ref"}). The Panel considers the effects of ethyl acrylate in the forestomach to be local and dependent on the concentration of ethyl acrylate. The concentration and exposure time, which induce the irritating effect in the forestomach would not be reached by exposure to ethyl acrylate via the use as a flavouring. Consequently, the Panel considers that the calculated chronic dietary exposure in adults and children would not be of safety concern.

4. Conclusions {#efs25012-sec-0027}
==============

The Panel concluded that ethyl acrylate is not genotoxic *in vivo* and that carcinogenic effects observed in rodent studies are not relevant to humans. Therefore, the Panel concluded that there is no safety concern for the use of ethyl acrylate as a flavouring substance in food, under the intended conditions of use.

5. Recommendations {#efs25012-sec-0028}
==================

The Panel takes note of other potential sources of dietary exposure such as from FCM. Exposure from plastic FCM could be up to the temporary TDI of 100 μg/kg bw per day, bringing the potential exposure from both plastic and flavouring above this TDI.​ The Commission may wish to take this into account.

Abbreviations {#efs25012-sec-0029}
=============

APETadded portions exposure techniquebwbody weightCAchromosomal aberrationsCASChemical Abstract ServiceCEFPanel on Food Contact Materials, Enzymes, Flavourings and Processing AidsCHLChinese hamster lung (cells)CHOChinese hamster ovary (cells)CoECouncil of EuropeFAOFood and Agriculture Organization of the United NationsFCMfood contact materialsFEMAFlavor and Extract Manufacturers AssociationFGEFlavouring Group EvaluationFLAVIS (FL)Flavour Information System (database)GSHglutathioneIARCInternational Agency for Research on CancerIDIdentityIRinfrared spectroscopyi.p.intraperitonealJECFAThe Joint FAO/WHO Expert Committee on Food AdditivesMNmicronucleiMSDIMaximised Survey‐derived Daily IntakeNCEnormochromatic erythrocyteNOAELno observed adverse effect levelNPSHnon‐protein sulfhydrylNTPNational Toxicology ProgramOECDOrganisation for Economic Cooperation and DevelopmentPCEpolychromatic erythrocytesSCEsister chromatid exchangesSCFScientific Committee on FoodSMLspecific migration limitSPETsingle portion exposure techniqueTDItolerable daily intakeWHOWorld Health Organization

Appendix A -- Genotoxicity data evaluated in FGE.71 {#efs25012-sec-1001}
===================================================

 {#efs25012-sec-0030}

###### 

Genotoxicity data on ethyl acrylate \[FL‐no: 09.037\] evaluated by JECFA ([2006](#efs25012-bib-0022){ref-type="ref"}) and considered by EFSA in FGE.71 (2010)

+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chemical name FL‐no JECFA‐no                                                                             | End‐point                                                                                                                                                                              | Test system                                                                                                                                      | Concentration                                                                               | Results                                                                                                                                         | Reference                                                                                                                                                             | Comments                                                                                                                       |
+==========================================================================================================+========================================================================================================================================================================================+==================================================================================================================================================+=============================================================================================+=================================================================================================================================================+=======================================================================================================================================================================+================================================================================================================================+
| ***In vitro***                                                                                           |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Ethyl acrylate                                                                                           | Reverse mutation                                                                                                                                                                       | *Salmonella* Typhimurium TA98, TA100,                                                                                                            | 30--2,000 μg/plate                                                                          | Negative[a](#efs25012-note-0018){ref-type="fn"}                                                                                                 | Waegemaekers and Bensink ([1984](#efs25012-bib-0047){ref-type="ref"})                                                                                                 | Reliable with the following restriction:                                                                                       |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| 09.037                                                                                                   |                                                                                                                                                                                        | TA1535, TA1537 and TA1538                                                                                                                        |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       | the study complied with current                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| 1351                                                                                                     |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       | recommendations with the exception that tester strains TA102 or *E. coli* WP2uvrA were not used                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S. *Typhimurium TA97, TA98,                                                                             | 33--3,333 μg/plate                                                                                                                                                                     | Negative[a](#efs25012-note-0018){ref-type="fn"} ^,^ [b](#efs25012-note-0019){ref-type="fn"}                                                      | Zeiger et al. ([1992](#efs25012-bib-0051){ref-type="ref"})                                  | Reliable with the following restriction:                                                                                                        |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| TA100 and TA1535                                                                                         |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | the study complied with current                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | recommendations with the exception that tester strains TA102 or *E. coli* WP2uvrA were not used                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S*. Typhimurium TA98,TA100,                                                                             | 100--10,000 μg/plate                                                                                                                                                                   | Equivocal[a](#efs25012-note-0018){ref-type="fn"} ^,^ [b](#efs25012-note-0019){ref-type="fn"} ^,^ [c](#efs25012-note-0020){ref-type="fn"}         | Haworth et al. ([1983](#efs25012-bib-0501){ref-type="ref"})                                 | Reliable with the following restriction:                                                                                                        |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| TA1535 and TA1537                                                                                        |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | the study complied with current                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | recommendations with the exception that tester strains TA102 or E. coli WP2*uvrA* were not used                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S*. Typhimurium TA98, TA100 and TA1537                                                                  | NR                                                                                                                                                                                     | Negative[a](#efs25012-note-0018){ref-type="fn"} ^,^ [b](#efs25012-note-0019){ref-type="fn"}                                                      | Ishidate et al. ([1981](#efs25012-bib-0021){ref-type="ref"})                                | No data reported                                                                                                                                |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S*. Typhimurium                                                                                         | ≤ 10,000 μg/plate                                                                                                                                                                      | Negative[a](#efs25012-note-0018){ref-type="fn"}                                                                                                  | Tennant et al. ([1987](#efs25012-bib-0044){ref-type="ref"})                                 | Reliable with restrictions (review paper without detailed results)                                                                              |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mitotic chromosomal                                                                                      | *Saccharomyces cerevisiae* D61.M                                                                                                                                                       | ≤ 1,095 μg/mL                                                                                                                                    | Negative[d](#efs25012-note-0021){ref-type="fn"} ^,^ [e](#efs25012-note-0022){ref-type="fn"} | Zimmermann and Mohr ([1992](#efs25012-bib-0052){ref-type="ref"})                                                                                | Reliable. Endpoint of low relevance, no OECD guideline available                                                                                                      |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| recombination                                                                                            |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S. cerevisiae* D61.M                                                                                    | ≤ 1,095 μg/mL                                                                                                                                                                          | Positive[d](#efs25012-note-0021){ref-type="fn"}                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| *S. cerevisiae* D61.M                                                                                    | ≤ 914 μg/mL                                                                                                                                                                            | Negative[e](#efs25012-note-0022){ref-type="fn"}                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Forward mutation                                                                                         | Mouse lymphoma L5178Y Tk+/− cells                                                                                                                                                      | 20 μg/mL                                                                                                                                         | Positive[f](#efs25012-note-0023){ref-type="fn"}                                             | Tennant et al. ([1987](#efs25012-bib-0044){ref-type="ref"})                                                                                     | Reliable with restrictions (review paper without detailed results)                                                                                                    |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse lymphoma L5178Y Tk+/− cells                                                                        | 10, 15, 20, 25, 27.5, 30, 32.5, 35, 40 or 50 μg/mL                                                                                                                                     | Positive[f](#efs25012-note-0023){ref-type="fn"} ^,^ [g](#efs25012-note-0024){ref-type="fn"}                                                      | Ciaccio et al. ([1998](#efs25012-bib-0002){ref-type="ref"})                                 | Reliable without restrictions. Study in line with OECD guideline No. 490                                                                        |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse lymphoma L5178Y Tk+/− cells                                                                        | 20, 25, 30 or 37.5 μg/mL                                                                                                                                                               | Positive[f](#efs25012-note-0023){ref-type="fn"} ^,^ [h](#efs25012-note-0025){ref-type="fn"}                                                      | Moore et al. ([1988](#efs25012-bib-0029){ref-type="ref"})                                   | Reliable without restrictions. Study in line with OECD guideline No. 490                                                                        |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | Large majority of mutants are small‐colony mutants                                                                                              |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse lymphoma L5178Y Tk+/− cells                                                                        | 2.5--40 μg/mL                                                                                                                                                                          | Positive[f](#efs25012-note-0023){ref-type="fn"} ^,^ [i](#efs25012-note-0026){ref-type="fn"}                                                      | McGregor et al. ([1988](#efs25012-bib-0027){ref-type="ref"})                                | Reliable without restrictions. Study in line with OECD guideline No. 490                                                                        |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | Positive only at highest dose. Equivocal using the 'global evaluation factor approach'                                                          |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chromosomal aberration                                                                                   | Chinese hamster ovary cells                                                                                                                                                            | 299 μg/mL                                                                                                                                        | Positive[j](#efs25012-note-0027){ref-type="fn"}                                             | Loveday et al. ([1990](#efs25012-bib-0026){ref-type="ref"})                                                                                     | Reliable without restrictions Study in line with OECD guideline No. 473                                                                                               |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        | \<29.9 μg/mL                                                                                                                                     | Negative[f](#efs25012-note-0023){ref-type="fn"} ^,^ [h](#efs25012-note-0025){ref-type="fn"} |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse lymphoma L5178Y Tk+/− cells                                                                        | 20, 25, 30 or 37.5 μg/mL                                                                                                                                                               | Positive[f](#efs25012-note-0023){ref-type="fn"} ^,^ [h](#efs25012-note-0025){ref-type="fn"}                                                      | Moore et al. ([1988](#efs25012-bib-0029){ref-type="ref"})                                   | Reliable without restrictions Study in line with OECD guideline No. 473                                                                         |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chinese hamster lung cells                                                                               | 0.0098 mg/mL[k](#efs25012-note-0028){ref-type="fn"}                                                                                                                                    | Positive[a](#efs25012-note-0018){ref-type="fn"}                                                                                                  | Ishidate et al. ([1981](#efs25012-bib-0021){ref-type="ref"})                                | Reliable with restrictions (review paper without detailed results)                                                                              |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          | (9.8 μg/mL)                                                                                                                                                                            |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chinese hamster ovary cells                                                                              | 299 μg/mL                                                                                                                                                                              | Positive[j](#efs25012-note-0027){ref-type="fn"}                                                                                                  | Tennant et al. ([1987](#efs25012-bib-0044){ref-type="ref"})                                 | Reliable with restrictions (review paper without detailed results)                                                                              |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        | Negative[f](#efs25012-note-0023){ref-type="fn"}                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Sister chromatid exchange                                                                                | Chinese hamster ovary cells                                                                                                                                                            | 150 μg/mL                                                                                                                                        | Positive[j](#efs25012-note-0027){ref-type="fn"}                                             | Reliable with restrictions (review paper without detailed results)                                                                              |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  | Negative[f](#efs25012-note-0023){ref-type="fn"}                                             | OECD guideline was withdrawn                                                                                                                    |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chinese hamster ovary cells                                                                              | 150 μg/mL                                                                                                                                                                              | Weak positive[j](#efs25012-note-0027){ref-type="fn"} Negative[f](#efs25012-note-0023){ref-type="fn"} ^,^ [h](#efs25012-note-0025){ref-type="fn"} | Loveday et al. ([1990](#efs25012-bib-0026){ref-type="ref"})                                 | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn)                                                    |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          | \<5 μg/mL                                                                                                                                                                              |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse lymphoma L5178Y Tk+/− cells                                                                        | 20.0--37.5 μg/mL                                                                                                                                                                       | Positive[f](#efs25012-note-0023){ref-type="fn"} ^,^ [h](#efs25012-note-0025){ref-type="fn"}                                                      | Moore et al. ([1988](#efs25012-bib-0029){ref-type="ref"})                                   | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn)                                                    |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Mouse splenocytes                                                                                        | 10--80 μg/mL                                                                                                                                                                           | Negative[l](#efs25012-note-0029){ref-type="fn"}                                                                                                  | Kligerman et al. ([1991](#efs25012-bib-0025){ref-type="ref"})                               | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn)                                                    |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  | 1--20 μg/mL                                                                                 | Negative[m](#efs25012-note-0030){ref-type="fn"}                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| ***In vivo***                                                                                            |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Ethyl acrylate                                                                                           | Sister chromatid exchange                                                                                                                                                              | Male C57BL/6 mice                                                                                                                                | 125, 250, 500 or 1,000 mg/kg[n](#efs25012-note-0031){ref-type="fn"}                         | Negative                                                                                                                                        | Kligerman et al. ([1991](#efs25012-bib-0025){ref-type="ref"})                                                                                                         | *In vivo‐vitro* study (animals were exposed, splenocytes were isolated and cultured *in vitro*) (OECD guideline was withdrawn) |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| 09.037                                                                                                   |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
| 1351                                                                                                     |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Chromosomal aberration                                                                                   | Male C57BL/6 mice                                                                                                                                                                      | 125, 250, 500 or 1,000 mg/kg[n](#efs25012-note-0031){ref-type="fn"}                                                                              | Negative                                                                                    | *In vivo‐vitro* study                                                                                                                           |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | (animals were exposed, splenocytes were isolated and cultured *in vitro*) this experimental protocol is not described in OECD guideline No. 475 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Micronucleus formation                                                                                   | Male C57BL/6 mice                                                                                                                                                                      | 125, 250, 500 or 1,000 mg/kg[n](#efs25012-note-0031){ref-type="fn"}                                                                              | Negative[q](#efs25012-note-0034){ref-type="fn"}                                             | Kligerman et al. ([1991](#efs25012-bib-0025){ref-type="ref"})                                                                                   | *In vivo‐vitro* study (animals were exposed, splenocytes were isolated and cultured *in vitro*) This experimental protocol is not described in OECD guideline No. 474 |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male BALB/c mice                                                                                         | 225--1,800 mg/kg[r](#efs25012-note-0035){ref-type="fn"}                                                                                                                                | Positive                                                                                                                                         | Przybojewska et al. ([1984](#efs25012-bib-0042){ref-type="ref"})                            | Reliable with restrictions: 4 animals/group were treated. Highest dose (1,800 mg/kg) was toxic. 2/4 animals died                                |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male and female C57BL/6 mice                                                                             | 461[n](#efs25012-note-0031){ref-type="fn"} ^,^ [s](#efs25012-note-0036){ref-type="fn"} or 738 mg/kg[n](#efs25012-note-0031){ref-type="fn"} ^,^ [t](#efs25012-note-0037){ref-type="fn"} | Negative                                                                                                                                         | Ashby et al. ([1989](#efs25012-bib-0001){ref-type="ref"})                                   | Reliable with restrictions (review paper)                                                                                                       |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male BALB/c mice                                                                                         | 812 mg/kg[u](#efs25012-note-0038){ref-type="fn"}                                                                                                                                       | Negative                                                                                                                                         |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male C57BL/6 mice                                                                                        | 738 mg/kg[u](#efs25012-note-0038){ref-type="fn"}                                                                                                                                       | Negative                                                                                                                                         |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male BDF~1~ mice                                                                                         | 188, 375 or 750 mg/kg[s](#efs25012-note-0036){ref-type="fn"} ^,^ [v](#efs25012-note-0039){ref-type="fn"}                                                                               | Negative                                                                                                                                         | Hara et al. ([1994](#efs25012-bib-0017){ref-type="ref"})                                    | Reliable with restrictions (poor reporting)                                                                                                     |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| 188, 375 or 750 mg/kg[w](#efs25012-note-0040){ref-type="fn"}                                             | Negative[x](#efs25012-note-0041){ref-type="fn"}                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| 375, 500 or 750 mg/kg[n](#efs25012-note-0031){ref-type="fn"} ^,^ [s](#efs25012-note-0036){ref-type="fn"} | Negative[x](#efs25012-note-0041){ref-type="fn"}                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Male BDF~1~ mice                                                                                         | 188, 375, 750 or 1,000 mg/kg[n](#efs25012-note-0031){ref-type="fn"} ^,^ [s](#efs25012-note-0036){ref-type="fn"} ^,^ [v](#efs25012-note-0039){ref-type="fn"}                            | Negative[y](#efs25012-note-0042){ref-type="fn"}                                                                                                  | Morita et al. ([1997](#efs25012-bib-0031){ref-type="ref"})                                  | Reliable with restrictions Basically following the OECD guidelines.                                                                             |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             |                                                                                                                                                 |                                                                                                                                                                       |                                                                                                                                |
|                                                                                                          |                                                                                                                                                                                        |                                                                                                                                                  |                                                                                             | Except that no data were reported on PCE/NCE ratio                                                                                              |                                                                                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| DNA alkaline elution                                                                                     | Male F344 rat forestomach squamous epithelium                                                                                                                                          | 0.1--4.0% (50--2,000 mg/kg)[v](#efs25012-note-0039){ref-type="fn"}                                                                               | Negative                                                                                    | Morimoto et al. ([1990](#efs25012-bib-0030){ref-type="ref"})                                                                                    | Reliable without restrictions. No OECD guidelines are available                                                                                                       |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Sex‐linked recessive lethal mutations                                                                    | *Drosophila melanogaster*                                                                                                                                                              | 20,000 mg/kg                                                                                                                                     | Negative[o](#efs25012-note-0032){ref-type="fn"}                                             | Valencia et al. ([1985](#efs25012-bib-0046){ref-type="ref"})                                                                                    | Reliable without restrictions. Low relevance of target organism. OECD guideline withdrawn                                                                             |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+
| Micronucleus formation                                                                                   | *D. melanogaster*                                                                                                                                                                      | 18,000; 20,000 or 40,000 mg/kg                                                                                                                   | Negative[p](#efs25012-note-0033){ref-type="fn"}                                             | Valencia et al. ([1985](#efs25012-bib-0046){ref-type="ref"})                                                                                    | Reliable without restrictions. Low relevance of target organism. No OECD guideline available                                                                          |                                                                                                                                |
+----------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+

OECD: Organisation for Economic Cooperation and Development; PCE: polychromatic erythrocyte; NCE: normochromatic erythrocyte.

With and without metabolic activation.

Pre‐incubation method.

The Ames tests were performed by two different laboratories, resulting in positive and negative results in the first and second experiments, respectively. The authors considered the results from the confirmation (second) experiment to be more definitive.

Cold shock regimen (i.e. 4‐h incubation at 28°C, followed by a 16‐h storage in an ice bath and a 4‐h incubation at 28°C).

Uninterrupted 16‐h incubation at 28°C.

Without metabolic activation.

Relative cell growth was 20% and 13%, respectively, at the two highest doses tested (40 and 50 μg/mL, respectively).

Cytotoxicity was observed at the highest dose tested.

Statistically significant increases in mutant fraction were observed at doses of 20 and 40 μg/mL.

With metabolic activation.

Dose at which chromosomal aberrations were detected in 20% of metaphase cells.

Exposure during the Go phase of the cell cycle. Cytotoxicity was observed at doses of \>30 μg/mL.

Exposure during the G‐S phase of the cell cycle. Cytotoxicity was observed at doses of \>10 μg/mL.

Administered intraperitoneally.

Injection experiment.

Feeding experiment.

A slight but significant increases in the frequency of micronucleus formation was observed at the highest dose tested (1000 mg/kg), which was thought to be due to an elevated frequency in one of the four treated mice.

Administered intraperitoneally in two doses within 24 h.

Assessment of bone marrow for formation of micronuclei 24 h after dosing.

Assessment of bone marrow for formation of micronuclei 24, 48 or 72 h after dosing.

Administered intraperitoneally at 0 and 24 h, followed by assessment of bone marrow for formation of micronuclei 6 h later.

Administered orally.

Administered orally twice within 24‐h.

A significant decrease in the reticulocyte ratio was observed at the highest dose tested compared with vehicle controls.

Mortality was observed at the highest dose tested (1,000 mg/kg).
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 {#efs25012-sec-0031}

###### 

*In vitro* genotoxicity studies on ethyl acrylate \[FL‐no: 09.037\]

+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| Chemical name FL‐no JECFA‐no                                          | End‐point                                                                                                                                                                                  | Test system                                                                                                                                                                              | Concentration                                                                                                                           | Results                                                                                                                                  | Reference                                                                                                                                           | Comments                                                                       |
+=======================================================================+============================================================================================================================================================================================+==========================================================================================================================================================================================+=========================================================================================================================================+==========================================================================================================================================+=====================================================================================================================================================+================================================================================+
| Ethyl acrylate                                                        | Ames test                                                                                                                                                                                  | *Salmonella* Typhimurium TA102                                                                                                                                                           | Up to 5,000 μg/plate                                                                                                                    | Negative                                                                                                                                 | Kirkland et al. ([2016](#efs25012-bib-0024){ref-type="ref"})                                                                                        | Reliable without restrictions. The study complies with OECD Test Guideline 471 |
|                                                                       |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
| 09.037                                                                |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
|                                                                       |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
| 1351                                                                  |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| *S*. Typhimurium strain YG7108, transformed with the plasmid pin3ERb5 | Up to 2,000 μg/plate                                                                                                                                                                       | Negative                                                                                                                                                                                 | Emmert et al. ([2006](#efs25012-bib-0006){ref-type="ref"})                                                                              | Reliable without restrictions. The study was designed to test the compound in a metabolically competent *S*. Typhimurium strain          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| Micronucleus Assay                                                    | [p53‐deficient rodent cell lines:]{.ul}                                                                                                                                                    | 0--20[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--8[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL  | Positive[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} | Fowler et al. ([2012a](#efs25012-bib-0007){ref-type="ref"})                                                                              | Reliable without restrictions In the short‐term treatment, MN were induced at concentrations of ethyl acrylate resulting in cytotoxicity of 50--60% |                                                                                |
|                                                                       |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
|                                                                       | V79                                                                                                                                                                                        |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          | The study was designed to investigate the different results in the MN assay depending on the cell line                                              |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| CHO                                                                   | 0--32[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--12[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL   | Positive[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; Negative[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| CHL                                                                   | 0--40[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--14[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL   | Positive[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"} ^and^ [a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"}    |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| [p53‐competent human cells:]{.ul}                                     | 0--50[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--10.4[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL | Positive[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; Negative[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
|                                                                       |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
| peripheral blood lymphocytes                                          |                                                                                                                                                                                            |                                                                                                                                                                                          |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| TK6 human lymphoblastoid cells                                        | 0--28[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--12[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL   | Positive[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; Negative[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| HepG2                                                                 | 0--96[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"}; 0--150[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} μg/mL  | Equivocal[a](#efs25012-note-0045){ref-type="fn"} ^,^ [b](#efs25012-note-0046){ref-type="fn"} Negative[a](#efs25012-note-0045){ref-type="fn"} ^,^ [c](#efs25012-note-0047){ref-type="fn"} |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| p53‐mutant mouse lymphoma L5178Y                                      | 0--18 μg/mL                                                                                                                                                                                | Equivocal in the absence of cytochalasin B                                                                                                                                               | Whitwell et al. ([2015](#efs25012-bib-0049){ref-type="ref"})                                                                            | Reliable without restrictions. The study was designed to investigate the possible role of p53 and apoptosis in the micronuclei induction |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| p53‐competent human lymphoblastoid TK6                                | 0--10 μg/mL                                                                                                                                                                                | Equivocal with both human cell linesin the presence of cytochalasin B                                                                                                                    |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+
| p53‐mutant human WIL2‐NS cells                                        | 0--9 μg/mL                                                                                                                                                                                 | Negative with both human cell lines in the absence of cytochalasin B                                                                                                                     |                                                                                                                                         |                                                                                                                                          |                                                                                                                                                     |                                                                                |
+-----------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------+

OECD: Organisation for Economic Cooperation and Development.

With metabolic activation.

Without metabolic activation.

3 h treatment + 21 h recovery.

24 h treatment + 0 h recovery.
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 {#efs25012-sec-0032}

**Calculation of the Dietary Exposure ‐ APET**

**Chronic Dietary Exposure --** [**'Added Portions Exposure Technique' (APET)**]{.ul} [5](#efs25012-note-1009){ref-type="fn"}

The chronic APET calculations are based on the normal combined occurrence level by adding the highest contributing portion of food and highest contributing portion of beverages (either among soft drinks or alcoholic beverages). APET for children is calculated by adding the highest contributing portion of food and highest contributing portion of beverages (among soft drinks). Furthermore, in the APET calculation for children, the portion sizes listed in Table 8 is adjusted by a factor 0.63 to take into account the smaller portion sizes consumed by the child.

[**Adults**]{.ul} **('Added Portions Exposure Technique' \[APET\])**

*On the basis of normal occurrence level from the added flavouring only*

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 μg/adult per day.

Beverage: The category 14.1 (Non‐alcoholic ('soft') beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 μg/adult per day.

The total APET will be 3,545 μg/adult per day corresponding to 59.1 μg/kg bw per day for a 60‐kg person.

[**Children**]{.ul} **(3‐year‐old child of 15 kg body weight)**

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 x 0.63 = 1,335 μg/child per day.

Beverage: The category 14.1 (Non‐alcoholic ('soft') beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 × 0.63 = 898 μg/child per day.

The total APET will be 2,233 μg/child per day corresponding to 149 μg/kg bw per day for a 15‐kg child.

*Conclusion*

The higher of the two values among adults and children, expressed per kg/bw per day, should be used as the basis for the safety evaluation of the candidate substance, i.e. the value of 150 μg/kg bw per day for a 15‐kg child should be compared to the appropriate no observed adverse effect level (NOAEL) for the candidate substance.

**Combined Dietary Exposure**

This is an estimate of total dietary exposure deriving from both the addition of the flavouring substance to foods and beverages and other dietary sources. To estimate the APET for combined dietary exposure, the occurrence of the substance in grapes and vanilla was also taken into account in the estimation.

[**Adults**]{.ul} **('Added Portions Exposure Technique' \[APET\])**

Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 μg/adult per day.

Beverage: The category 14.1 (Non‐alcoholic ('soft') beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 μg/adult per day.

The total APET will be 3,545 μg/adult per day corresponding to 59.1 μg/kg bw per day for a 60‐kg person.

[**Children**]{.ul} **(3‐year‐old child of 15 kg body weight)**

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 × 0.63 = 1,335 μg/child per day.

Beverage: The category 14.1 (Non‐alcoholic ('soft') beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 × 0.63 = 898 μg/child per day.

The total APET will be 2,233 μg/child per day corresponding to 149 μg/kg bw per day for a 15‐kg child.

###### 

Normal and maximum occurrence levels for refined categories of foods and beverages

  Food categories[a](#efs25012-note-0048){ref-type="fn"}   Standard portions[b](#efs25012-note-0049){ref-type="fn"} (g)                                                                                                                                                                       Occurrence level as added flavouring substance (mg/kg)   Occurrence level from other sources[c](#efs25012-note-0050){ref-type="fn"} (mg/kg)   Combined occurrence level from all sources[e](#efs25012-note-0052){ref-type="fn"} (mg/kg)                       
  -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----- ----- ------- -------
  **01.1**                                                 Milk and dairy‐based drinks                                                                                                                                                                                                        200                                                      10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.2**                                                 Fermented and renneted milk products (plain), excluding food category 01.1.2 (dairy‐based drinks)                                                                                                                                  200                                                      10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.3**                                                 Condensed milk and analogues (plain)                                                                                                                                                                                               70                                                       10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.4**                                                 Cream (plain) and the like                                                                                                                                                                                                         15                                                       10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.5**                                                 Milk powder and cream powder and powder analogues (plain)                                                                                                                                                                          30                                                       10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.6**                                                 Cheese and analogues                                                                                                                                                                                                               40                                                       10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.7**                                                 Dairy‐based desserts (e.g. pudding, fruit or flavoured yoghurt)                                                                                                                                                                    125                                                      10.6                                                                                 15.2                                                                                                    10.6    15.2
  **01.8**                                                 Whey and whey products, excluding whey cheeses                                                                                                                                                                                     200                                                      10.6                                                                                 15.2                                                                                                    10.6    15.2
  **02.1**                                                 Fats and oils essentially free from water                                                                                                                                                                                          15                                                                                                                                                                                                                                                            
  **02.2**                                                 Fat emulsions mainly of type water‐in‐oil                                                                                                                                                                                          15                                                                                                                                                                                                                                                            
  **02.3**                                                 Fat emulsions mainly of type water‐in‐oil, including mixed and/or flavoured products based on fat emulsions                                                                                                                        15                                                                                                                                                                                                                                                            
  **02.4**                                                 Fat‐based desserts excluding dairy‐based dessert products of category 1.7                                                                                                                                                          50                                                                                                                                                                                                                                                            
  **03.0**                                                 Edible ices, including sherbet and sorbet                                                                                                                                                                                          50                                                                                                                                                                                                                                                            
  **04.1.1**                                               Fresh fruit                                                                                                                                                                                                                        140                                                                                                                                                                                                                                       0.1   0.1   0.1     0.1
  **04.1.2**                                               Processed fruit                                                                                                                                                                                                                    125                                                                                                                                                                                                                                       0.1   0.1   0.1     0.1
  **04.1.2.5**                                             Jams, jellies, marmalades                                                                                                                                                                                                          30                                                                                                                                                                                                                                                            
  **04.2.1**                                               Fresh vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed                                                                                                   200                                                                                                                                                                                                                                                           
  **04.2.2**                                               Processed vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed purees and spreads (e.g. peanut butter) and nuts and seeds                                    200                                                                                                                                                                                                                                                           
  **04.2.2.5**                                             Vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed purees and spreads (e.g. peanut butter)                                                                 30                                                                                                                                                                                                                                                            
  **05.1**                                                 Cocoa products and chocolate products, including imitations and chocolate substitutes                                                                                                                                              40                                                       10.14                                                                                13.3                                                                                                    10.14   13.3
  **05.1.3**                                               Cocoa‐based spreads, including fillings                                                                                                                                                                                            30                                                       10.14                                                                                13.3                                                                                                    10.14   13.3
  **05.2**                                                 Confectionery, including hard and soft candy, nougats, etc., other than 05.1, 05.3 and 05.4                                                                                                                                        30                                                       10.14                                                                                13.3                                                                                                    10.14   13.3
  **05.3**                                                 Chewing gum                                                                                                                                                                                                                        3                                                        0.07                                                                                 0.11                                                                                                    0.07    0.11
  **05.4**                                                 Decorations (e.g. for fine bakery wares), toppings (non‐fruit) and sweet sauces                                                                                                                                                    35                                                       10.14                                                                                13.3                                                                                                    10.14   13.3
  **06.1**                                                 Whole, broken or flaked grain, including rice                                                                                                                                                                                      200                                                      6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.2**                                                 Flours and starches (including soya bean powder)                                                                                                                                                                                   30                                                       6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.3**                                                 Breakfast cereals, including rolled oats                                                                                                                                                                                           30                                                       6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.4**                                                 Pastas and noodles and like products (e.g. rice paper, rice vermicelli, soya bean pastas and noodles)                                                                                                                              200                                                      6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.5**                                                 Cereal‐ and starch‐based desserts (e.g. rice pudding, tapioca pudding)                                                                                                                                                             200                                                      6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.6**                                                 Batters (e.g. for breading or batters for fish or poultry)                                                                                                                                                                         30                                                       6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.7**                                                 Pre‐cooked or processed rice products, including rice cakes (Oriental type only)                                                                                                                                                   200                                                      6.77                                                                                 10.84                                                                                                   6.77    10.84
  **06.8**                                                 Soya bean products (excluding soya bean products of food category 12.9 and fermented soya bean products of food category 12.10)                                                                                                    100                                                      6.77                                                                                 10.84                                                                                                   6.77    10.84
  **07.1**                                                 Bread and ordinary bakery wares                                                                                                                                                                                                    50                                                       11.75                                                                                13.76                                                                                                   11.75   13.76
  **07.2**                                                 Fine bakery wares (sweet, salty, savoury) and mixes                                                                                                                                                                                80                                                       11.75                                                                                13.76                                                                                                   11.75   13.76
  **08.1**                                                 Fresh meat, poultry and game                                                                                                                                                                                                       200                                                      0.1                                                                                  0.1                                                                                                     0.1     0.1
  **08.2**                                                 Processed meat, poultry and game products in whole pieces or cuts                                                                                                                                                                  100                                                      0.1                                                                                  0.1                                                                                                     0.1     0.1
  **08.3**                                                 Processed comminute meat, poultry and game products                                                                                                                                                                                100                                                      0.1                                                                                  0.1                                                                                                     0.1     0.1
  **08.4**                                                 Edible casings (e.g. sausage casings)                                                                                                                                                                                              1                                                        0.1                                                                                  0.1                                                                                                     0.1     0.1
  **09.1.1**                                               Fresh fish                                                                                                                                                                                                                         200                                                                                                                                                                                                                                                           
  **09.1.2**                                               Fresh molluscs, crustaceans and echinoderms                                                                                                                                                                                        200                                                                                                                                                                                                                                                           
  **09.2**                                                 Processed fish and fish products, including molluscs, crustaceans and echinoderms                                                                                                                                                  100                                                                                                                                                                                                                                                           
  **09.3**                                                 Semi‐preserved fish and fish products, including molluscs, crustaceans and echinoderms                                                                                                                                             100                                                                                                                                                                                                                                                           
  **09.4**                                                 Fully preserved, including canned or fermented, fish and fish products, including molluscs, crustaceans and echinoderms                                                                                                            100                                                                                                                                                                                                                                                           
  **10.1**                                                 Fresh eggs                                                                                                                                                                                                                         100                                                                                                                                                                                                                                                           
  **10.2**                                                 Egg products                                                                                                                                                                                                                       100                                                                                                                                                                                                                                                           
  **10.3**                                                 Preserved eggs, including alkaline. salted and canned eggs                                                                                                                                                                         100                                                                                                                                                                                                                                                           
  **10.4**                                                 Egg‐based desserts (e.g. custard)                                                                                                                                                                                                  125                                                                                                                                                                                                                                                           
  **11.1**                                                 Refined and raw sugar                                                                                                                                                                                                              10                                                                                                                                                                                                                                                            
  **11.2**                                                 Brown sugar excluding products of food category 11.1                                                                                                                                                                               10                                                                                                                                                                                                                                                            
  **11.3**                                                 Sugar solutions and syrups, and (partially) inverted sugars, including molasses and treacle, excluding products of food category 11.1.3 (soft white sugar, soft brown sugar, glucose syrup, dried glucose syrup, raw cane sugar)   30                                                                                                                                                                                                                                                            
  **11.4**                                                 Other sugars and syrups (e.g. xylose, maple syrup, sugar toppings)                                                                                                                                                                 30                                                                                                                                                                                                                                                            
  **11.5**                                                 Honey                                                                                                                                                                                                                              15                                                                                                                                                                                                                                                            
  **11.6**                                                 Table‐top sweeteners, including those containing high‐intensity sweeteners                                                                                                                                                         1                                                                                                                                                                                                                                                             
  **12.1**                                                 Salt and salt substitutes                                                                                                                                                                                                          1                                                                                                                                                                                                                                                             
  **12.10**                                                Protein products other than from soybeans                                                                                                                                                                                          15                                                                                                                                                                                                                                                            
  **12.2**                                                 Herbs, spices, seasonings and condiments (e.g. seasoning for instant noodles)                                                                                                                                                      1                                                                                                                                                                                                                                                             
  **12.3**                                                 Vinegars                                                                                                                                                                                                                           15                                                                                                                                                                                                                                                            
  **12.4**                                                 Mustards                                                                                                                                                                                                                           15                                                                                                                                                                                                                                                            
  **12.5**                                                 Soups and broths                                                                                                                                                                                                                   200                                                                                                                                                                                                                                                           
  **12.6**                                                 Sauces and like products                                                                                                                                                                                                           30                                                                                                                                                                                                                                                            
  **12.7.a**                                               Salads 120 g (e.g. macaroni salad, potato salad) excluding cocoa‐ and nut‐based spreads of food categories                                                                                                                         120                                                                                                                                                                                                                                                           
  **12.7.b**                                               Sandwich spreads (20 g), excluding cocoa‐ and nut‐based spreads of food categories                                                                                                                                                 20                                                                                                                                                                                                                                                            
  **12.8**                                                 Yeast and like products                                                                                                                                                                                                            1                                                                                                                                                                                                                                                             
  **12.9**                                                 Soybean‐based seasonings and condiments                                                                                                                                                                                            15                                                                                                                                                                                                                                                            
  **12.9.1**                                               Fermented soya bean products (e.g. miso)                                                                                                                                                                                           40                                                                                                                                                                                                                                                            
  **12.9.2**                                               Soybean sauce                                                                                                                                                                                                                      15                                                                                                                                                                                                                                                            
  **12.9.3**                                               Fermented soybean sauce                                                                                                                                                                                                            15                                                                                                                                                                                                                                                            
  **13.2.a**                                               Complementary foods for infants and young children: Dry instant cereals (with or without milk), including pasta                                                                                                                    110                                                                                                                                                                                                                                                           
  **13.2.b**                                               Complementary foods for infants and young children: Meat‐based or fish‐based dinner                                                                                                                                                170                                                                                                                                                                                                                                                           
  **13.2.c**                                               Complementary foods for infants and young children: Dairy‐based dessert                                                                                                                                                            110                                                                                                                                                                                                                                                           
  **13.2.d**                                               Complementary foods for infants and young children: Vegetables, potatoes, broth, soups, pulses                                                                                                                                     170                                                                                                                                                                                                                                                           
  **13.2.e**                                               Complementary foods for infants and young children: Biscuits and cookies                                                                                                                                                           20                                                                                                                                                                                                                                                            
  **13.2.f**                                               Complementary foods for infants and young children: Fruit purée                                                                                                                                                                    110                                                                                                                                                                                                                                                           
  **13.2.g**                                               Complementary foods for infants and young children: Fruit juice                                                                                                                                                                    120                                                                                                                                                                                                                                                           
  **13.2.h**                                               Milk for young children                                                                                                                                                                                                            200                                                                                                                                                                                                                                                           
  **13.3**                                                 Dietetic foods intended for special medical purposes (excluding food products of category 13.1 'Infant formulae, follow‐up formulae and other formulae for special medical purposes for infants')                                  200                                                                                                                                                                                                                                                           
  **13.4**                                                 Dietetic formulae for slimming purposes and weight reduction                                                                                                                                                                       200                                                                                                                                                                                                                                                           
  **13.5**                                                 Dietetic foods (e.g. supplementary foods for dietary use), excluding products of food categories 13.1 (Infant formulae, follow‐up formulae and other formulae for special medical purposes for infants), 13.2--13.4 and 13.6       200                                                                                                                                                                                                                                                           
  **13.6**                                                 Food supplements                                                                                                                                                                                                                   5                                                                                                                                                                                                                                                             
  **14.1**                                                 Other non‐alcoholic ('soft') beverages (expressed as liquid)                                                                                                                                                                       300                                                      4.75                                                                                 8.75                                                                                                    4.75    8.75
  **14.2.1**                                               Beer and malt beverages                                                                                                                                                                                                            300                                                      0.38                                                                                 1                                                                                                       0.38    1
  **14.2.2**                                               Cider and perry                                                                                                                                                                                                                    300                                                      0.38                                                                                 1                                                                                                       0.38    1
  **14.2.3**                                               Grape wines                                                                                                                                                                                                                        150                                                      0.38                                                                                 1                                                                                                       0.38    1
  **14.2.4**                                               Wines (other than grape)                                                                                                                                                                                                           150                                                      0.38                                                                                 1                                                                                                       0.38    1
  **14.2.5**                                               Mead                                                                                                                                                                                                                               150                                                      0.38                                                                                 1                                                                                                       0.38    1
  **14.2.6**                                               Distilled spirituous beverages containing more than 15% alcohol                                                                                                                                                                    30                                                       0.38                                                                                 1                                                                                                       0.38    1
  **14.2.7**                                               Aromatised alcoholic beverages (e.g. beer, wine and spirituous cooler‐type beverages, low alcoholic refreshers)                                                                                                                    300                                                      0.38                                                                                 1                                                                                                       0.38    1
  **15.1**                                                 Snacks, potato‐, cereal‐, flour‐ or starch‐based (from roots and tubers, pulses and legumes)                                                                                                                                       30                                                                                                                                                                                                                                                            
  **15.2**                                                 Processed nuts, including coated nuts and nut mixtures (with e.g. dried fruit)                                                                                                                                                     30                                                                                                                                                                                                                                                            
  **15.3**                                                 Snacks -- fish‐based                                                                                                                                                                                                               30                                                                                                                                                                                                                                                            
  **16.0**                                                 Composite foods (e.g. casseroles, meat pies, mincemeat) -- foods that could not be placed in categories 01--15                                                                                                                     300                                                                                                                                                                                                                                                           

Most of the categories reported are the sub‐categories of Codex GSFA (General Standard for Food Additives, available at <http://www.codexalimentarius.net/gsfaonline/CXS_192e.pdf>), used by the JECFA in the SPET technique (FAO/WHO, [2008](#efs25012-bib-0502){ref-type="ref"}). In the case of category 13.2 (complementary foods for infants and young children), further refined categories have been created so that a specific assessment of dietary exposure can be performed in young children.

For Adults. In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product label or one of the standard dilution factors established by the JECFA (FAO/WHO, [2008](#efs25012-bib-0502){ref-type="ref"}): --1/25 for powder used to prepare water‐based drinks such as coffee, containing no additional ingredients,--1/10 for powder used to prepare water‐based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),--1/7 for powder used to prepare milk, soups and puddings,--1/3 for condensed milk.

As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.

In order to estimate normal values in each category, only foods and beverages in which the substance is present in significant amount will be considered (e.g. for the category 'Fresh fruit' 04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the flavouring substance is known to occur).

As added flavouring or from other sources. The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels from added use to that from other sources or by expert judgement based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use levels.
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Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1--24.
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The APET has been calculated based on the occurrence levels in the food subcategories reported in the above table, with the exclusion of categories 13.2 (complementary foods for infants and young children).
